R&D | February 18, 2026
Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Subscribe To Our Newsletter & Stay Updated
